Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.

Oncogene - 22 Jun 2000

Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny M V, Fojo T

Abstract excerpt

The efficacy of anticancer therapy is limited by the development of drug resistance. While the role of p53 in the intrinsic sensitivity of human cancer cells to paclitaxel (PTX) remains controversial, its role in acquired paclitaxel resistance has never been addressed. In this study we examined the p53 status of three paclitaxel selected human ovarian carcinoma sublines, resistant to paclitaxel due to acquired...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cyclins

Share to Gene Amplification

Share to Genetic Vectors

Share to In Situ Hybridization, Fluorescence

Share to Paclitaxel

Share to Tubulin

Source

Identifiers

PMID: 10871860
DOI: 10.1038/sj.onc.1203642

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.PMID 10871860Read ↗

Normal p53 status and function despite the development of drug resistance in human breast cancer cells.Semantic proximity Read ↗

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.Semantic proximity Read ↗

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.Semantic proximity Read ↗

Human mutations that confer paclitaxel resistance.Semantic proximity Read ↗

Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic ManipulationSemantic proximity Read ↗

Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism.Semantic proximity Read ↗

Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.Semantic proximity Read ↗

Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53.Semantic proximity Read ↗

Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation.Semantic proximity Read ↗

Inactivation of p53 in a Human Ovarian Cancer Cell Line Increases the Sensitivity to Paclitaxel by Inducing G2/M Arrest and ApoptosisSemantic proximity Read ↗

Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependentSemantic proximity Read ↗

Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.